Hypertension in organ transplant recipients is associated with several functional modifications of the renin angiotensin system (RAS), which varies according to the type of transplanted organs (kidney, heart, liver or bone marrow) and the immunosuppressive regimen. Before transplantation, chronic organ failure is associated with direct and indirect stimulation of both systemic and local RASs. After transplantation, cyclosporin per se is the major determinant of hypertension. It induces
Introduction
Hypertension is well known to be closely related with functional modifications of the renin angiotensin system (RAS). However, the effects of transplantation on the RAS have been a source of conflicting results and can be summarised by an apparent paradox: 'why is hypertension almost universal after transplantation, since it is observed among 25% of the recipients under azathioprine and up to more than 75% of them under cyclosporin, whereas plasma renin activity (PRA) levels appear normal or slightly elevated?' Such an apparent paradox is only related to heterogeneity in the physiopathology of hypertension, according to species variations between animal experiments and human, differences in experimental conditions at time of RAS explorations, the type of transplanted organ (kidney, heart, liver, bone marrow) and the immunosuppressive regimen. The purpose of this review is to summarise the main data obtained in the past 10 years to explain these conflicting results.
A classical concept of the RAS ( Figure 1 ) describes a circulation-borne endocrine system, the elements of which are secreted by various organs. 1 The components and sources of this biochemical cascade include: (1) The renin substrate, angiotensinogen, which originates from the liver. (2) Renin from the kidney, which is released from juxtaglomerular cells as both prorenin, or inactive renin, and active renin. In human, prorenin normally makes up more than half of circulating renin. 2 Direct measure of total immunoreactive renin and of active renin, by immunoradiometric assays, gives better quantification of endogenous renin production than the results of PRA levels, which only measure the rate of Angiotensin I generation in vivo.
3,4 (3) Angiotensin I (ANG I) is then converted to the physiologically active Angiotensin II (ANG II) by the angiotensinconverting enzyme (ACE), a non-specific carboxypeptidase with ubiquitous distribution. The circulating form of ACE is synthesised by vascular endothelial cells, monocytes and macrophages and its circulating levels are genetically determined. 5 ANG II interacts with highly specific membranous receptors on target organs to produce vasoconstriction and maintain blood volume and pressure homeostasis via: (a) the kidney with increased Na + proximal tubular reabsorption, efferent arteriolar vasoconstriction; (b) the adrenal cortex with increased aldosterone synthesis and production; (c) the peripheral vessels, with increased systemic arteriolar vasoconstriction; (d) and the heart with positive chronotropic effects due to noradrenaline release from the sympathetic nervous system. 1 The circulating RAS can be acutely activated with important short term effects in blood pressure (BP) regulation. RAS inhibitors reduce BP in hypertensive conditions marked by elevated PRA. 6 However, renin inhibitors, 7 converting enzyme inhibitors 6 and more recently ANG II receptor antagonists 8 can lower BP levels during hypertension even if PRA is low or within the normal range. Such results and information brought by molecular biology led to the discovery of local paracrine RASs in diverse tissues such as the arterial wall, kidney, heart, adrenal cortex and central nervous system, which may be regulated independently from their circulating counterparts. Current knowledge on their normal function 9, 10 can be summarised as follows: (1) Proteins and peptides exchanges between plasma and tissues are constant. (2) Angiotensinogen originates predominantly from the liver, but use of isolated perfused organs and molecular biology have shown mRNA expression and production within the heart and the kidney. Steroids increase angiotensinogen production by the liver and also by the heart. (3) Active renin is secreted by the kidney only, which is the only site of conversion from prorenin to active renin. (4) Both renin and angiotensinogen largely diffuse within the interstitium. (5) Circulating ANG I originates from the plasma for 20% only and 80% are produced by tissular reaction and extraplasmatic ANG I production is effectively correlated with PRA. (6) ACE is ubiquitous and synthesised by all vascular endothelium, but 90-99% of ACE is found in the tissue and only 1-10% in the circulation. (7) ANG II receptors are specifically located within the tissues. While the absolute autonomy of several local RASs is uncertain, the presence of renal, vascular and heart local RAS has been well established by in situ hybridisation studies. mRNA expression and tissue RAS components are now well demonstrated in kidney, vessels and heart, which exert a long term effect, not only on vasoconstriction, sodium and water, but which also contribute to structural adaptation with glomerular hyperplasia, vascular hypertrophy and myocardial hypertrophy. The role of local renal RAS is particularly relevant during chronic renal disease with increased renal renin activity in the presence of low to normal PRA levels.
11 Both circulating and local RASs components will be directly or indirectly modified by transplantation.
Stimulation of the RAS is commonly observed during chronic organ failure preceeding transplantation ( Figure 2 ). (1) Na retention due to end-stage renal failure is usually marked by low to normal PRA with limited information regarding systemic ANG II. Indirect evidence for PRA increase is suggested by the increased number of ANG II receptors at least in some renal diseases. Moreover, a higher renin content in the residual nephrons suggest increased secretion of active renin and prorenin from the remnant nephrons. 12 Therefore, despite low to normal PRA values during chronic renal failure, activity of the renal RAS can be increased. Such stimulation may account for the beneficial effects of converting enzyme inhibitors, which slow the progression of renal failure. 13 (2) Advanced stages of chronic heart failure (stage III or IV NYHA) are associated with chronic stimulation of both systemic and local RASs 14 due to sympathetic stimulation and renal hypoperfusion. 15 The influence of RAS and the benefits from RAS inhibition have been demonstrated by use of ACE inhibitors, which increase both short and long-term haemodynamics and patients survival. 16 (3) Advanced liver failure is associated with normal plasma angiotensinogen levels, although its hepatic synthesis could be diminished. PRA and aldosterone levels are increased due to low systemic resistances and high circulating glucagon, a powerful splanchnic vasodilator. 17 Vasodilation appears as a primary event leading to sodium retention by the kidney with subsequent volume expansion and ascites formation, low BP and elevated cardiac output. Use of spironolactones is classical to counteract stimulation of the RAS in this setting. (4) Before bone marrow transplantation, chemotherapy and irradiation may induce direct systemic and renal vascular toxicity with potential stimulation of local RAS. 18 Therefore, whatever the type of organ failure, RASs chronic stimulation that is constant before the graft and inhibition of the system appears to be benefical during kidney, heart and/or liver failure with slower progression of the disease.
Apart from immunosuppression, many factors will contribute to intrinsic stimulation of both systemic and local RAS after organ transplantation (Figure 3) .
(1) After kidney transplantation, any condition associated with renal ischaemia may induce RAS stimulation. The native kidneys may contribute to increased renin secretion, as demonstrated by response of hypertension to bilateral nephrectomy and/or to converting enzyme inhibitors, which also increase renal graft blood flow. 19 This suggests that the native kidneys participate in vasoconstriction of the graft. Acute graft rejection with fall in glomerular fitration rate (GFR) and natriuresis induces local ischaemia and acute stimulation of both systemic and renal RAS. Chronic rejection and/or recurrence of initial diseases are associated with hyperfiltration and renal vasoconstriction, due to increased ANG II with consequent fall in renal functional reserve. 20 Although renal transplant artery stenosis is a theoretical one kidney-one artery Goldblatt model of hypertension with increased blood volume and normal PRA, 21 in this setting renal hypoperfusion can induce local RAS stimulation.
(2) After cardiac transplantation, haemodynamic parameters stimulate the RAS, when there is evidence of left ventricular dysfunction, but abnormal response to volume expansion, with salt and water retention, can be observed with normal cardiac index. 22 The role of the central nervous system and of cardiac denervation is still debated. However, denervation of the transplanted heart could disinhibit the cardiorenal neuroendocrine reflex mechanism and account for an increase in renal nerve activity, renal vascular resistances, PRA, ANG II and aldosterone with a fall in GFR, as recently shown by Braith in heart transplant recipients who failed to suppress PRA, ANG II and aldosterone during serum saline infusion. 23 Among the other hormonal systems interacting with RAS stimulation, the role of plasma atrial natriuretic factor (ANF), arginine vasopressin (AVP) and catecholamines have to be considered. In order to analyse mechanisms of water and Na + retention during the week after cardiac transplantation, we daily studied eight transplant recipients with delayed introduction of cyclosporin on day 3 to 4. 24 Despite normal cardiac output, we observed sustained high PRA and fall in FeNa + up to day 6 after the graft with increased aldosterone levels, which were back to normal on day 3 only. Plasma ANF was elevated and ADH was always within the normal range. Therefore, sustained stimulation of the RAS appeared the main determinant of water and Na retention during the week after cardiac transplantation and before treatment by cyclosporin. In this study, 24 PRA levels were effectively correlated with plasma ANF suggesting close interregulation within the two systems. However, high plasma ANF failed to mitigate the blunted natriuresis, as also found by other studies in cardiac recipients. 25 In a very nice recent double-blind study, 25 Singer showed that hormonal patterns were similar in 12 cardiac transplant recipients, healthy subjects and untreated essential hypertension, since 5 days of low sodium diet (10 mmoles daily) induced effective stimulation of the RAS in the three groups with similar qualitative responses. Such results demonstrate that cardiac denervation does not influence the effects of the baroreflex on renin release in response to low sodium intake. However, after 5 days of high sodium intake (350 mmoles daily), PRA and aldosterone were less suppressed in cardiac transplant recipients than in healthy subjects, suggesting that either reduced baroreceptor outflow or cyclosporin per se were responsible for failure to suppress the renin normally. 25 (3) There is no evidence for early stimulation of the RAS after liver transplantation. 26 In a study performed by Navasa 17 among 12 liver transplant recipients, Cardiac Index and peripheral vascular resistances were back to normal 2 weeks after transplantation as well as previous elevation in PRA, aldosterone and glucagon levels which were significantly lower than before liver transplantation. When Braith 23 analysed the endocrine responses to acute volume expansion in six liver and 10 heart transplant recipients under similar doses of cyclosporin with same renal function, the liver transplant recipients behaved as the seven normal controls (healthy volunteers) with an adapted suppression of PRA, ANG II and aldosterone levels during saline infusion, whereas heart transplant recipients demonstrated trouble in sodium excretion with failure to suppress the RAS.
Immunosuppression per se induces important modifications of the RAS systems after transplantation ( Figure 4) . (1) Several drugs, such as azathioprine, have little or no effect. During bone marrow transplantation indirect stimulation of both renal and systemic RAS may be induced by vascular toxicity 18 due to irradiation and renal insufficiency due to drugs nephrotoxicity. (2) Synthetic glucocorticoids induce indirect suppression of systemic and renal RASs since their mineralocorticoid effect increase blood volume. 27 They also exert direct RAS suppression, as shown by cortisol infusion and/or oral steroids administration in healthy volunteers, which induce a fall in active renin and in ANG II, with no change in prorenin and a classical increase in angiotensinogen. 28 (3) Both experimental data and human studies suggest that cyclosporin (Cy) stimulates the RAS through at least three major mechanisms ( Figure 5) .
First, Cy direct and dose-dependent nephrotoxicity has been related to the drug's intrinsic renal ischaemic effect. As shown by Bantle, 29 among 10 renal transplant recipients under cyclosporin compared to 10 others under azathioprine and seven patients with renal insufficiency, cyclosporin induces a significant fall in GFR and in effective renal plasma flow, which is related to direct vasoconstriction of glomerular afferent arterioles and increase in renal vascular resistances. In the long term, Cy nephrotoxicity 30, 31 is responsible for chronic renal disease and progressive decline in renal function, as demonstrated by Myers since 1988 31 in cardiac transplant recipients under high doses of cyclosporin (up to 17 mg/kg daily) compared to those receiving azathioprine. Therefore, acute and chronic renal ischaemia due to direct Cy nephrotoxicity increase renin release and ANG II production, which in turn favours sodium retention with enhanced vascular sensitivity to ANG II and increased peripheral resistances. 32, 33 Such results explain the benefit from the use of converting enzyme inhibitors in rats to reduce Cy nephotoxicity and/or to prevent the onset of post-transplant hypertension. 34 However, Na + retention can also be due to altered Na + excretion at a tubular level, a specific abnormality probably related to Cy nephrotoxicity. 32 Second, the effects of cyclosporin per se on renin production have long been controversial, but both initial works by Myers 30, 31 and recent studies 35 suggest that de novo hypertension after transplantation could be a direct renin dependent hypertension. Using primary cell cultures from rat renal cortex, Kurtz 36 found that cyclosporin A (CsA) stimulated renin secretion three-fold and this stimulation was paralleled by a dose dependent two-fold increase in inactive renin within the cells, whereas intracellular active renin remained the same. Initial studies by Figure 5 Cyclosporin stimulates both systemic and local RASs.
Bantle 29 in kidney transplant recipients and by Bellet 37 in heart transplant recipients showed no stimulation of the system in view of normal PRA values. These results were interpreted as the result of extracellular fluid volume expansion. When we explored 21 cardiac (CTR) and 12 liver (LTR) hypertensive transplant recipients with similar renal function on normal salt diet, plus 19 normotensive controls in the same age range, individual values of supine and upright PRA tended to be higher in cardiac and in liver transplant recipients compared to controls, although not significantly. 35 However, plasma levels of active renin and of total renin in both the supine and upright positions were significantly higher in transplant recipients compared to healthy volunteers, and total renin was three to fourfold higher in hypertensive cardiac and liver transplant recipients compared to controls. In addition, we found a weak but significant negative correlation between urinary sodium excretion and active renin in CTR and LTR. Our results agreed with early work from Myers 31 during the long-term course of chronic nephropathy in cardiac transplant recipients, when he had shown a striking increase in inactive renin and lower PRA values under high doses of cyclosporin compared to azathioprine. Increase in prorenin is an early marker of vascular complications among insulin-dependent diabetics. 38, 39 Biochemical meaning of increased prorenin induced by cyclosporin still has to be elucidated. It could be related either to a lower clearance of prorenin or to a dysregulation at the level of gene transcription, as suggested by Kahan, 40 and/or to partial blockade in the intrarenal conversion of inactive to active renin. 41 A third mechanism involved in RAS stimulation by cyclosporin is sympathetic stimulation, which has been suggested by early experiments in rats 42 and was confirmed by Scherrer in humans 43 with striking increases in sympathetic nerve activity and in peripheral vascular resistances in cardiac transplant recipients under cyclosporin with consequent direct stimulation of the RAS.
Therefore, the past 10 years have enabled us to accumulate enough evidence of both systemic and local RAS stimulation by cyclosporin via both direct and indirect effects. Cyclosporin induces direct vasoconstriction within the kidney 30, 31, 33 and the peripheral vessels, 44 with consequent renal ischaemia, increased vascular resistances and RAS stimulation with an increase in ANG II production. Cyclosporin also indirectly modifies the local RASs, within the kidney, the vessels and the heart, 45 since its peripheral effects combine both enhancement of the vasoconstriction induced by ANG II, catecholamines and TXA2 and inhibition of the vasodilation due to prostacycline release. 46 Further explanation to the apparent cyclosporin paradox will come from future therapeutic studies, which should elucidate the potential benefit from RAS inhibition. Two important questions should be elucidated: (1) does RAS inhibition effectively counteract cyclosporin chronic stimulation of the system with decreased nephrotoxicity and renal ischaemia and lower peripheral vasoconstriction? (2) what is the real need for simultaneous volume depletion during cyclosporin-induced hypertension, 47 since Na + retention is directly induced by the steroids and the effects of cyclosporin nephrotoxicity, which in turn both contribute to normal or little elevation in PRA?
